Document Detail

Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
MedLine Citation:
PMID:  20808678     Owner:  NLM     Status:  MEDLINE    
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters were used to assess the cardiac function. The median follow-ups were 54 months in the dexrazoxane group and 86 months in the control group. The mean cumulative doses of doxorubicin were 280.8+/-83.4 mg/m(2) in the dexrazoxane group and 266.1+/-75.0 mg/m(2) in the control group. The dexrazoxane group experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of early and late anthracycline cardiotoxicity in childhood solid tumors.
Hyoung Soo Choi; Eun Sil Park; Hyoung Jin Kang; Hee Young Shin; Chung Il Noh; Yong Soo Yun; Hyo Seop Ahn; Jung Yun Choi
Related Documents :
2645478 - The use of inotropic agents in acute and chronic congestive heart failure.
7786668 - Reversal of haemochromatotic cardiomyopathy in beta thalassaemia by chelation therapy.
20808678 - Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
15147368 - Purging iron from the heart.
2330088 - Communicating hydrocephalus in adults: prediction of outcome after ventricular shunting...
11458708 - Cardiac vagal chemosensory afferents. function in pathophysiological states.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-12
Journal Detail:
Title:  Journal of Korean medical science     Volume:  25     ISSN:  1598-6357     ISO Abbreviation:  J. Korean Med. Sci.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-22     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8703518     Medline TA:  J Korean Med Sci     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  1336-42     Citation Subset:  IM    
Department of Pediatrics, Seoul National University Bundang Hospital, Sungnam, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / adverse effects*
Cardiomyopathies / chemically induced,  prevention & control
Cardiovascular Agents / therapeutic use*
Child, Preschool
Cohort Studies
Disease-Free Survival
Doxorubicin / adverse effects*
Follow-Up Studies
Heart Failure / chemically induced,  prevention & control
Neoplasms / drug therapy*,  mortality
Razoxane / therapeutic use*
Ventricular Function, Left / physiology
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Cardiovascular Agents; 21416-87-5/Razoxane; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stress-induced alterations in mast cell numbers and proteinase-activated receptor-2 expression of th...
Next Document:  Birth outcomes of Koreans by birthplace of infants and their mothers, the United States versus Korea...